Today, the 10th April, 2018, the Extraordinary General Meeting of SynAct Pharma AB (publ) was held. The following is a summary of the decisions taken. The decision was taken with the required majority.
Approval of the Board of Director’s decision on the rights issue
The meeting determined to increase the company’s share capital by a maximum of SEK 282,214,75 through a new issue of no more than 2,257,718 shares at a subscription price of SEK 9.90 per share. The total amount of the issue amounts to a maximum of SEK 22,351,408.20.
The following terms and conditions shall apply to the issue:
- The issue shall give precedence to the shareholders of the company. One (1) subscription right can be redeemed for each existing share. Eleven (11) such subscription rights entitles the holder to subscribe to two (2) new shares.
- The record date in the share register kept by Euroclear Sweden AB for determining which shareholders are entitled to participate in the issue with preferential rights shall be 13th April 2018. Others can also subscribe to the issue
- SEK 9.90 should be paid for each subscribed share.
- Subscription to shares shall take place between 19th April 2018 and 8th May 2018 inclusive. Subscription with the support of preferential rights shall occur with simultaneous payment. Subscriptions made without the support of subscription rights shall be made on a special subscription list and payment shall be made no later than the fourth banking day following the dispatch of the allocation notice to the subscriber. The Board of Directors shall be entitled to extend the period of subscription and payment.
- In the event that not all shares with preferential rights are subscribed as above, the Board of Directors shall decide on the allocation of shares, within the limits of the issue’s maximum amount, to other shareholders who have subscribed to shares without preferential rights, and decide how that allocation should be made. In the first instance, the allocation of new shares subscribed for without subscription rights shall be made to subscribers who also subscribed for new shares with subscription rights, irrespective of whether the subscriber was a shareholder on the record date or not, and in the event that they cannot be fully allocated, shares shall be allocated pro rata in relation to the number of subscription rights used for the subscription of new shares and, if this cannot be done, by drawing lots. In the second instance, the allocation of new shares subscribed for without subscription rights shall be made to others who have subscribed without subscription rights, and in the event that allocation to them cannot be made fully, the allocation shall be pro rata in relation to the number of new shares subscribed and, in so far as this cannot be done, by drawing lots.
- The new shares shall first be entitled to dividends on the record date for dividends that occurs immediately after the new shares are registered at the Swedish Companies Registration office.
- The Board of Directors or the board’s appointee is authorised to decide on minor corrections required for registration at the Swedish Companies Registration Office and Euroclear Sweden AB.
Lund, April 2018
SynAct Pharma AB (publ)
THE BOARD OF DIRECTORS
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
Telephone: +45 28 44 75 67 Telephone: +45 40 15 66 69
E-mail: [email protected] E-mail: tj@synactpharma.com